These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36978857)

  • 1. Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn
    Karlsson JOG; Jynge P; Ignarro LJ
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca
    Karlsson JOG; Jynge P
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx.
    Karlsson JOG; Jynge P; Ignarro LJ
    Antioxidants (Basel); 2021 Dec; 10(12):. PubMed ID: 34943040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).
    Pfeiffer P; Lustberg M; Näsström J; Carlsson S; Persson A; Nagahama F; Cavaletti G; Glimelius B; Muro K
    JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36308441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
    Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
    Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).
    Karlsson JOG; Andersson RG; Jynge P
    Transl Oncol; 2017 Aug; 10(4):641-649. PubMed ID: 28668762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity.
    Canta A; Chiorazzi A; Pozzi E; Fumagalli G; Monza L; Meregalli C; Carozzi VA; Rodriguez-Menendez V; Oggioni N; Näsström J; Marmiroli P; Cavaletti G
    Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32645985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity.
    Sałat K
    Pharmacol Rep; 2020 Jun; 72(3):508-527. PubMed ID: 32347537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
    Simpson D; Dunn C; Curran M; Goa KL
    Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced neuropathy and colo-rectal cancer patient's quality of life: Practical lessons from a prospective cross-sectional, real-world study.
    Prutianu I; Alexa-Stratulat T; Cristea EO; Nicolau A; Moisuc DC; Covrig AA; Ivanov K; Croitoru AE; Miron MI; Dinu MI; Ivanov AV; Marinca MV; Radu I; Gafton B
    World J Clin Cases; 2022 Apr; 10(10):3101-3112. PubMed ID: 35647128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
    Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
    Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
    J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy.
    Vitale MG; Barbato C; Crispo A; Habetswallner F; Martino BM; Riccardi F; Maione A; Eisenwagen S; Vitale G; Cartenì G
    Molecules; 2020 May; 25(10):. PubMed ID: 32414185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that fodipir (DPDP) binds neurotoxic Pt
    Stehr JE; Lundström I; Karlsson JOG
    Sci Rep; 2019 Nov; 9(1):15813. PubMed ID: 31676855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
    Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
    BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.